Axitinib

For research use only. Not for use in humans.

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

55 publications

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Axitinib has been cited by 55 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M{DOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMECwNFUyOyEQvF2= M33hcnNCVkeHUh?=
NCI-H1703 NH7UW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3UfoRwUUN3ME2wMlAxODlyMjFOwG0> MkjsV2FPT0WU
KASUMI-1 MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:yR2lEPTB;MD6wNFY5OiEQvF2= MkLLV2FPT0WU
CGTH-W-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3STWM2OD1yLkCwO|IzKM7:TR?= NG\GeZVUSU6JRWK=
A204 NVTUeWNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXnbHdKSzVyPUCuNFA6QTJizszN NYfOdG97W0GQR1XS
HOP-62 NYX0cnhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXKfG04UUN3ME2wMlExQDN4IN88US=> NG\OWVRUSU6JRWK=
H-EMC-SS NV\5SHlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PtRmlEPTB;MD6xNVAxPSEQvF2= NVHy[GZIW0GQR1XS
KU812 NGni[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMU[1O|ch|ryP MYrTRW5ITVJ?
EM-2 M{H1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Tkd2lEPTB;MD6xOlgyPiEQvF2= NX7xZ4xUW0GQR1XS
LAMA-84 M1nYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD1TG9UUUN3ME2wMlE4PjZ3IN88US=> NIrIWJBUSU6JRWK=
JAR Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M36yOGlEPTB;MD6yN|k5QSEQvF2= Mor6V2FPT0WU
G-361 NYH3dXFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXUW5VKSzVyPUCuN|I{OjVizszN MVHTRW5ITVJ?
KG-1 NH30bJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHGTWM2OD1yLkO3OlQzKM7:TR?= NIPUN5hUSU6JRWK=
BV-173 NGfQXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHMS2VKSzVyPUCuN|k{OiEQvF2= NFj0OldUSU6JRWK=
K5 NIK5TpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELqTlZKSzVyPUCuOFIyOjdizszN NUTKe2N5W0GQR1XS
MEG-01 NYC0dXZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYOxfoJHUUN3ME2wMlQzOzZzIN88US=> MoTtV2FPT0WU
MFM-223 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XwcmlEPTB;MD60OFc4PiEQvF2= NGDUdWdUSU6JRWK=
BE-13 Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn35TWM2OD1yLkWxNFA5KM7:TR?= MVLTRW5ITVJ?
NEC8 MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULRU3hrUUN3ME2wMlczOTF|IN88US=> NGDKelVUSU6JRWK=
SW756 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe4SZlKSzVyPUCuPVk5PDZizszN NE[2d5hUSU6JRWK=
A2780 MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFwMEGxOFYh|ryP MmC5V2FPT0WU
NB14 MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwMEG4NFEh|ryP M1HnXHNCVkeHUh?=
H4 M1Wye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nq[2lEPTB;MT6wOlQzOiEQvF2= M2\YeHNCVkeHUh?=
SK-OV-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXXZ|lJUUN3ME2xMlA3PjN|IN88US=> NGPxXHVUSU6JRWK=
AN3-CA NV\xbYJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTFwMEizPFkh|ryP Ml7VV2FPT0WU
A427 NFHkSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH21OFRKSzVyPUGuNVA{QDFizszN MlrlV2FPT0WU
ES7 Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFwMUGzN|Qh|ryP MnvwV2FPT0WU
AGS MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4npVWlEPTB;MT6xNVM6PSEQvF2= MYnTRW5ITVJ?
G-402 NEHsUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLtPI9KSzVyPUGuNVQ3QTRizszN NGi2cFJUSU6JRWK=
ES5 MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLVV|JKSzVyPUGuNVczPDhizszN M3rBWXNCVkeHUh?=
DEL NELnVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO3c5U4UUN3ME2xMlI2PDV5IN88US=> MYjTRW5ITVJ?
NB10 Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHucoZKSzVyPUGuN|I2PTdizszN M3jKPXNCVkeHUh?=
NCI-H1581 NYT2[HdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmexTWM2OD1zLkO5NFQzKM7:TR?= NUXqN3VqW0GQR1XS
D-566MG M3W4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFwNEC2PFMh|ryP MmrnV2FPT0WU
LXF-289 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DYfmlEPTB;MT60N|k6PiEQvF2= MWHTRW5ITVJ?
BT-549 NX;nc4ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDBdZhKSzVyPUGuOVY6ODlizszN NXrQUohrW0GQR1XS
NKM-1 M1HvcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFwNkC1OVYh|ryP MkjtV2FPT0WU
SW780 MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHznTXZKSzVyPUGuOlUyPThizszN MYnTRW5ITVJ?
NCI-H292 Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LCVmlEPTB;MT62OlM5OyEQvF2= M1WzWXNCVkeHUh?=
HMV-II NW\NZnNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjIbVRKSzVyPUGuO|A1QDhizszN MoLqV2FPT0WU
ALL-PO MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HjTWlEPTB;MT64NFAyPSEQvF2= Mn\qV2FPT0WU
UACC-257 NVPBZmNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFwOEKxOlMh|ryP NWqzU5hlW0GQR1XS
PA-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XFOGlEPTB;MT64NlczPSEQvF2= NIfySHhUSU6JRWK=
HD-MY-Z NWf4OYlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki2TWM2OD1zLki2NlgyKM7:TR?= MojQV2FPT0WU
HSC-4 NELkbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwOUO4N|kh|ryP NELGe3RUSU6JRWK=
GCT NUDpVI5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHhSllKSzVyPUKuNFA6OTZizszN NF3zXIZUSU6JRWK=
RT-112 NV;Lb2l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWK0XZVUUUN3ME2yMlE{PDJ2IN88US=> NIDXWW9USU6JRWK=
A172 MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDCTWM2OD1{LkGzOlA3KM7:TR?= M1\TOHNCVkeHUh?=
HCE-T NV2yOpo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPSTWM2OD1{LkKwOVk5KM7:TR?= NHTqW2tUSU6JRWK=
YH-13 NWfzeZA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe1foQyUUN3ME2yMlIyPjdzIN88US=> MVjTRW5ITVJ?
DK-MG NIq0WXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO2dY5OUUN3ME2yMlI{QDN2IN88US=> NEnTem5USU6JRWK=
ACN MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJwMkO4O|Uh|ryP MVTTRW5ITVJ?
VA-ES-BJ NV32Z3h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJwMkS5OVch|ryP M3O0cnNCVkeHUh?=
L-363 NFnPZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDBTWM2OD1{LkK4NFYyKM7:TR?= NIK1[3VUSU6JRWK=
HuH-7 MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrGTGRKSzVyPUKuOFIyPjVizszN NVzCRWJEW0GQR1XS
A4-Fuk NWC0c3I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkT0TWM2OD1{LkS3NVY5KM7:TR?= M1L0PHNCVkeHUh?=
T-24 NGX3PYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDDTWM2OD1{LkS4NFM4KM7:TR?= MULTRW5ITVJ?
GOTO NVrTSJFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmSxTWM2OD1{LkWzNFE{KM7:TR?= MVnTRW5ITVJ?
MV-4-11 NV\n[FlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3xTWM2OD1{LkW5NVY6KM7:TR?= M4XSb3NCVkeHUh?=
DMS-114 M3LmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJwNk[zOFUh|ryP M1XrcXNCVkeHUh?=
MHH-NB-11 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorxTWM2OD1{LkewNlk6KM7:TR?= NFnzWYVUSU6JRWK=
CHP-212 NH;QRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLTfnJKSzVyPUKuPFIxQTFizszN NEXCR4lUSU6JRWK=
DMS-273 M4W5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\jXppKSzVyPUKuPVAzODdizszN MkLoV2FPT0WU
SF295 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm1TWM2OD1|LkCyOVk4KM7:TR?= MU\TRW5ITVJ?
NCI-H1563 M33XfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTNwMUWwNFUh|ryP NFWyPVRUSU6JRWK=
NCI-H446 MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;ETWM2OD1|LkKyPFA2KM7:TR?= MWPTRW5ITVJ?
HCC1806 NYPjUJhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX2TWM2OD1|LkK3OlU4KM7:TR?= NGXYZpZUSU6JRWK=
SF126 MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\xTWM2OD1|LkOwNFE4KM7:TR?= NWXPT|ZOW0GQR1XS
SW982 NXzw[GJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\UTWM2OD1|LkOzPFc2KM7:TR?= NIHJWFlUSU6JRWK=
ES8 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTNwM{S5PVkh|ryP MoXHV2FPT0WU
SCC-4 NH3rfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTNwNUCzPVYh|ryP M3nRVHNCVkeHUh?=
RPMI-8226 M2fWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi1NZYzUUN3ME2zMlYzPjF4IN88US=> MlvyV2FPT0WU
EW-11 NXX3V3pGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXSTWM2OD1|Lk[zNFIzKM7:TR?= NUXCe41mW0GQR1XS
COR-L105 NVXpNIRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTNwNkOzN|Qh|ryP MXHTRW5ITVJ?
ES1 NXvUS3BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7x[FNKUUN3ME2zMlg{ODl2IN88US=> NX\FO2E6W0GQR1XS
KMOE-2 M4HyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzFTWM2OD1|LkmxPFA5KM7:TR?= NYn3d211W0GQR1XS
ABC-1 NWHENGhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrNbYh[UUN3ME2zMlk{QTFzIN88US=> Ml24V2FPT0WU
NCI-H526 M2T0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTNwOUmxNlYh|ryP Mo\TV2FPT0WU
HCC1395 NF;VTnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX2TWM2OD1|Lkm5OFg1KM7:TR?= NFrVd45USU6JRWK=
DU-145 M4Lwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\Te3hKSzVyPUSuNVI5OjVizszN MlPqV2FPT0WU
JEG-3 Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTRwMUW5NVYh|ryP NWntfml[W0GQR1XS
HCC1187 MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPwe49KSzVyPUSuNlE2QTdizszN NIPQOHpUSU6JRWK=
LC-2-ad M{XxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrMWGRKSzVyPUSuNlIyPzdizszN NIfIbWtUSU6JRWK=
ONS-76 M3nnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXzeVdrUUN3ME20MlI1OTl{IN88US=> M3voVnNCVkeHUh?=
CAL-27 M4CxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrMfWxKSzVyPUSuNlQ{PDRizszN MkHzV2FPT0WU
8-MG-BA MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTRwMk[2OVgh|ryP MnzGV2FPT0WU
HGC-27 Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTRwMkm2OkDPxE1? M3\3[3NCVkeHUh?=
Hs-578-T NGTRZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj2TWM2OD12LkOxOFY5KM7:TR?= M{LEU3NCVkeHUh?=
EW-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXHTWM2OD12LkWzNFE1KM7:TR?= MV\TRW5ITVJ?
SW1573 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTRwNUWxOlMh|ryP M1zTZ3NCVkeHUh?=
SNU-423 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTRwNkC3PUDPxE1? NGPiR|lUSU6JRWK=
HOS NUeycIdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7jTWM2OD12Lk[5O|ch|ryP MXTTRW5ITVJ?
LB1047-RCC M4i0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fOSmlEPTB;ND64NVQyQCEQvF2= MnyzV2FPT0WU
ChaGo-K-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS4TWM2OD12Lki5NFQ5KM7:TR?= NIHq[3dUSU6JRWK=
A3-KAW MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTRwOUezOVIh|ryP M3L6dnNCVkeHUh?=
CAS-1 MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TPS2lEPTB;ND65PVkxQCEQvF2= NV;EdG43W0GQR1XS
NBsusSR M4XyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIiySYJKSzVyPUWuNFM2OTRizszN MnLRV2FPT0WU
KM12 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3njSmlEPTB;NT6yPVgzPyEQvF2= MkfjV2FPT0WU
NCI-H1155 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ft[mlEPTB;NT6zPFE5PSEQvF2= MYrTRW5ITVJ?
EFM-19 NVzkdJU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XDeWlEPTB;NT60NVc{PyEQvF2= Mm\BV2FPT0WU
D-392MG M3LwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nWWGlEPTB;NT61O|g1QSEQvF2= M{\PfXNCVkeHUh?=
JVM-3 M1jldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnNbmhKSzVyPUWuO|I{OjVizszN MlXPV2FPT0WU
EW-16 M1LzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL6RlJpUUN3ME21Mlc2PTh|IN88US=> NIrPbYRUSU6JRWK=
KARPAS-45 NUHvZWR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTVwOESzNlUh|ryP MlTHV2FPT0WU
NCI-H28 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf5UVdKSzVyPUWuPFc6OThizszN M170dHNCVkeHUh?=
COLO-829 NYDOc5E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjvfpZHUUN3ME21MlkyPTB2IN88US=> MWPTRW5ITVJ?
KM-H2 M3TvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfCV21vUUN3ME21MlkzOzl3IN88US=> MoP2V2FPT0WU
NCI-H82 NEP4Ro1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTVwOUK3O|Eh|ryP MnnLV2FPT0WU
OAW-42 NFzjS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq4TZJKSzVyPUWuPVg5OjFizszN M{Pob3NCVkeHUh?=
A704 MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjaS4d5UUN3ME22MlExPTd2IN88US=> NXO1dGg6W0GQR1XS
NCI-H1048 MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzBVXFRUUN3ME22MlExPTl7IN88US=> NEOwSm1USU6JRWK=
LOXIMVI NIfIblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLZTWM2OD14LkGxNlQ5KM7:TR?= NGTZbnJUSU6JRWK=
MKN45 M1TOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\yZ5FoUUN3ME22MlI3ODF4IN88US=> NXLtSnlGW0GQR1XS
D-502MG MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVOwTW1JUUN3ME22MlI5QDV5IN88US=> NV\0UYVqW0GQR1XS
HUTU-80 MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TJW2lEPTB;Nj60NVY5QCEQvF2= M1XRS3NCVkeHUh?=
S-117 M4LzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCwcGFuUUN3ME22MlUxOjZ5IN88US=> M1HqVHNCVkeHUh?=
HCC1569 NGXS[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TRSGlEPTB;Nj61N|c{PyEQvF2= MYDTRW5ITVJ?
J-RT3-T3-5 NYjKWW9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rxWmlEPTB;Nj61OFU4OiEQvF2= M{\ZZnNCVkeHUh?=
OC-314 NIX3dpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PINWlEPTB;Nj65NVE2QSEQvF2= NVLENlU6W0GQR1XS
SNU-449 NHTFZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;vSYtCUUN3ME23MlAyODd{IN88US=> NXK2PYpkW0GQR1XS
NCI-H720 NH3OOJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTdwMUmzOFUh|ryP MV7TRW5ITVJ?
KP-N-YS NGj4dnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XJbmlEPTB;Nz6yNFczKM7:TR?= NXfN[XVnW0GQR1XS
IGROV-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPye2pIUUN3ME23MlMzOzh4IN88US=> M3nQcHNCVkeHUh?=
SK-PN-DW MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrBSZlDUUN3ME23MlQ5OTVizszN MWfTRW5ITVJ?
HCC1419 M{\ROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFi1TnNKSzVyPUeuOVMh|ryP NXyxNHh5W0GQR1XS
HAL-01 MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml2zTWM2OD15Lk[wOlQ1KM7:TR?= MkfrV2FPT0WU
HCC2998 NGHLRVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTdwNkC3OFMh|ryP MnfLV2FPT0WU
SK-N-FI M3v5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL5TWM2OD15Lk[zNFM{KM7:TR?= NIDHOnZUSU6JRWK=
GI-ME-N Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTdwNkS5N|Qh|ryP NYf4UmZEW0GQR1XS
SW1088 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n6d2lEPTB;Nz62OVgzPiEQvF2= MmfSV2FPT0WU
IA-LM MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrwdXgxUUN3ME23MlY5PjF|IN88US=> Mo[1V2FPT0WU
SK-NEP-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LzTWlEPTB;Nz62PVYyKM7:TR?= M1TGU3NCVkeHUh?=
MDA-MB-415 MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTdwOEmxPFYh|ryP NFSyOo1USU6JRWK=
COLO-800 M1HwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\Gb3NEUUN3ME23Mlk1PDl{IN88US=> NH\JcGJUSU6JRWK=
NCI-H2228 NEjkSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnSTWM2OD16LkG1O|g{KM7:TR?= MVXTRW5ITVJ?
D-423MG M3rsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDzTWM2OD16LkKxO|Ih|ryP M{LmT3NCVkeHUh?=
TE-1 M2XXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXzbmJKSzVyPUiuOFQ{OTZizszN NUPCS4J5W0GQR1XS
NOS-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXGZpA3UUN3ME24MlUyPTN2IN88US=> Moe5V2FPT0WU
8505C NGntTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXMTWM2OD16Lk[0PFI1KM7:TR?= MVTTRW5ITVJ?
HEC-1 MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H4TmlEPTB;OD63PFQ{QSEQvF2= MYfTRW5ITVJ?
TE-11 NELQ[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDQNWszUUN3ME24Mlk6PTVzIN88US=> NGHle2xUSU6JRWK=
CTB-1 M1XpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTlwMEG0N|Mh|ryP MnjkV2FPT0WU
TGBC11TKB Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TIdGlEPTB;OT6wNlI1OSEQvF2= MUXTRW5ITVJ?
NB17 Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrpVmY1UUN3ME25MlE5QDdizszN MULTRW5ITVJ?
Becker MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX2wZpRtUUN3ME25MlQyQTR2IN88US=> NGLlTZpUSU6JRWK=
SN12C MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVW4[mJ[UUN3ME25MlQ2OjN2IN88US=> M1rxWXNCVkeHUh?=
COLO-320-HSR MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jX[2lEPTB;OT62NFI{PyEQvF2= MoDyV2FPT0WU
D-283MED M2XUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly3TWM2OD17Lk[zNFczKM7:TR?= MXrTRW5ITVJ?
D-263MG NInubFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz1R5VKSzVyPUmuPFM{QDRizszN M{TjZXNCVkeHUh?=
MEL-JUSO MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW5TWM2OD17LkmwNVI4KM7:TR?= MoftV2FPT0WU
T98G NFH2d21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTWTWM2OD17LkmwNlA{KM7:TR?= NH;EfG1USU6JRWK=
HLE M2LiSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrUOoQ4UUN3ME25MlkxQTB7IN88US=> Mn7sV2FPT0WU
Ca9-22 M3vlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTFyLkC2OlUh|ryP NFO1ZXpUSU6JRWK=
OS-RC-2 MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnNVY1LUUN3ME2xNE4yODR3IN88US=> M{\iR3NCVkeHUh?=
T47D MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HvWWlEPTB;MUCuNVU2KM7:TR?= M{nJSXNCVkeHUh?=
GI-1 MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm3TWM2OD1zMD6zOVM{KM7:TR?= M1LFSnNCVkeHUh?=
NUGC-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFyLkS0NFIh|ryP NELMXpRUSU6JRWK=
MDA-MB-361 NVy0TY5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnlcmRKSzVyPUGwMlQ1OzJizszN MmTVV2FPT0WU
SCC-15 M3u5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW5S4ZKSzVyPUGwMlQ4OThizszN NHqwemhUSU6JRWK=
KS-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnriTWM2OD1zMD62N|AyKM7:TR?= NIPVZXBUSU6JRWK=
CAL-12T NVjzPJczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\sZW9wUUN3ME2xNE43OzZzIN88US=> MVrTRW5ITVJ?
OVCAR-4 NUXnZnl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLnTWM2OD1zMD63NFY5KM7:TR?= MoraV2FPT0WU
HuP-T4 M2jUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLoZotYUUN3ME2xNU4xOzJ6IN88US=> MnTWV2FPT0WU
NCI-H358 NXrOPW94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGix[4NKSzVyPUGxMlI3PTdizszN Mn2yV2FPT0WU
HO-1-N-1 MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfhXpVDUUN3ME2xNU4{Ozl6IN88US=> M{LORnNCVkeHUh?=
NH-12 NFrvTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmroTWM2OD1zMT61N|c5KM7:TR?= MUPTRW5ITVJ?
MOLT-4 M4nPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq3TWM2OD1zMT61PVg2KM7:TR?= MU\TRW5ITVJ?
K-562 NEe2W|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[0TWM2OD1zMT63NlQ5KM7:TR?= MVjTRW5ITVJ?
ES6 M4TweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\qfmp3UUN3ME2xNU45PThzIN88US=> NUOxRmFFW0GQR1XS
RO82-W-1 MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXETWM2OD1zMT65NFY1KM7:TR?= M172eHNCVkeHUh?=
Ramos-2G6-4C10 NV:1eodCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFzLkmzNkDPxE1? NXvtXnliW0GQR1XS
23132-87 NIHOd|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnDZm9MUUN3ME2xNk4xQDJzIN88US=> Mo[zV2FPT0WU
A549 NEL3bnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXOWIRKSzVyPUGyMlMzQDVizszN Ml;QV2FPT0WU
NCI-H23 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTF{LkWwNlYh|ryP MlfOV2FPT0WU
H9 NHLYUYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e3OmlEPTB;MUKuOVU4PyEQvF2= NUe3dohiW0GQR1XS
LB771-HNC Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInMeXZKSzVyPUGyMlc3PSEQvF2= NIGxdoZUSU6JRWK=
QIMR-WIL MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HUUGlEPTB;MUKuPFI2QCEQvF2= MlLmV2FPT0WU
HSC-3 NVj6WndIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF{LkmyO|Yh|ryP NIfuWIFUSU6JRWK=
PFSK-1 NULr[XJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF{Lkm1NFch|ryP MnHTV2FPT0WU
ETK-1 NWLPcYlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojiTWM2OD1zMz6wO|c6KM7:TR?= NHW1WFhUSU6JRWK=
SW1710 NFHsNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vYeGlEPTB;MUOuN|Y1OSEQvF2= NIO0c3dUSU6JRWK=
COLO-684 M{K4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHQN4JKSzVyPUGzMlQ2PDFizszN M2\4XHNCVkeHUh?=
RPMI-7951 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK3TWM2OD1zMz61NVM3KM7:TR?= M2nXc3NCVkeHUh?=
A101D NHLrbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn6TWM2OD1zMz61N|Q6KM7:TR?= NIT6OJBUSU6JRWK=
KE-37 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPGUnZKSzVyPUGzMlU5QDdizszN NFW2UI5USU6JRWK=
SiHa MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnhO5B{UUN3ME2xN{45OzR4IN88US=> M1GwVnNCVkeHUh?=
NCI-H226 MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTF|Lki4NFgh|ryP MYPTRW5ITVJ?
DB NUnlW|Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELJdmZKSzVyPUGzMlk6OjhizszN NE\aNXFUSU6JRWK=
HT-1197 NHn6ZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXkTWM2OD1zND6wPFA6KM7:TR?= NGT3U|hUSU6JRWK=
SBC-5 NXjuXHFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\UemlEPTB;MUSuNVM3OiEQvF2= NI\4bHJUSU6JRWK=
VMRC-RCZ M1q3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHUTWM2OD1zND61O|c1KM7:TR?= M1LmVnNCVkeHUh?=
697 M3XmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\OS2lnUUN3ME2xOE43OjdizszN NV;zdG1lW0GQR1XS
OMC-1 Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF2Lke4PFgh|ryP NFXMdVdUSU6JRWK=
SKG-IIIa NEHQUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;3Z2hbUUN3ME2xOE45ODBzIN88US=> MlPGV2FPT0WU
DOK M3\ibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG0NlN1UUN3ME2xOE46QTN|IN88US=> M1f5RnNCVkeHUh?=
NCI-H2029 Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojFTWM2OD1zNT6zOlAzKM7:TR?= MY\TRW5ITVJ?
NCI-H2009 NUXVVYFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF3LkWwPVUh|ryP M4fRVXNCVkeHUh?=
LK-2 NIjrcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr6cIlKSzVyPUG1MlY1PDlizszN M3v5dHNCVkeHUh?=
NCI-H661 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rWUWlEPTB;MUWuPVA4PSEQvF2= M1HLenNCVkeHUh?=
GT3TKB MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPhWpNKSzVyPUG2MlA3PzZizszN NICzUpFUSU6JRWK=
GP5d MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF4LkO0NkDPxE1? Mo[wV2FPT0WU
SK-MEL-2 NVu4WIRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HNXGlEPTB;MU[uOFQ5PSEQvF2= NWfoc|RVW0GQR1XS
SK-UT-1 M2XFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF4LkW2OUDPxE1? MkftV2FPT0WU
NB7 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[5PFZMUUN3ME2xOk43QTdzIN88US=> M2jLPXNCVkeHUh?=
NCI-H460 NFvSemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF4LkezNlYh|ryP NI\ZcWpUSU6JRWK=
8305C M1;2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK0UmlGUUN3ME2xOk44QDd5IN88US=> M3v4XHNCVkeHUh?=
CaR-1 NIPyfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nCSGlEPTB;MU[uPFEyOSEQvF2= M2nZTXNCVkeHUh?=
D-247MG NYjPSXVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTwXlJLUUN3ME2xOk45PjJ3IN88US=> MWLTRW5ITVJ?
LoVo MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLsTHFKSzVyPUG2Mlk1QDhizszN MoOyV2FPT0WU
NCI-H2405 NWnFWXZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi0dnFXUUN3ME2xO{4yQTB6IN88US=> NYnWfHlDW0GQR1XS
AU565 NYCyV5R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF5LkKyOUDPxE1? NUDscotZW0GQR1XS
OCI-AML2 NEGyNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj2TWM2OD1zNz61N|E4KM7:TR?= NFXvcVVUSU6JRWK=
22RV1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfZPGZKSzVyPUG3MlU5QDRizszN NXTUT2xiW0GQR1XS
HT-144 M4\0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF5Lk[1PVgh|ryP NYTQeXd[W0GQR1XS
HuO9 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TOeGlEPTB;MUeuO|A{OSEQvF2= M2fp[XNCVkeHUh?=
Daoy MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPkeHBKSzVyPUG3MlcyQDRizszN NXv4Z3ZTW0GQR1XS
SJRH30 NYDIenR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTF5Lki0PFkh|ryP NIixfJFUSU6JRWK=
CHL-1 NYXvWnJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHUOHpKSzVyPUG3MlkzPDlizszN MYLTRW5ITVJ?
J82 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm3Z2Q1UUN3ME2xO{46PjN3IN88US=> NYDB[FBxW0GQR1XS
COR-L23 NX;h[phET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XpeGlEPTB;MUiuNFAyOSEQvF2= NYXKR49sW0GQR1XS
SNU-C2B M4jSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;rfmlEPTB;MUiuNlI4PiEQvF2= Ml33V2FPT0WU
NCI-H1770 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jQemlEPTB;MUiuOFYyPSEQvF2= MlzZV2FPT0WU
MHH-PREB-1 MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX6ZoVKSzVyPUG4MlU3QTdizszN NEXaeZRUSU6JRWK=
ES3 M3f1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTLSnpNUUN3ME2xPE42QDh|IN88US=> MlrQV2FPT0WU
MDA-MB-231 M2ixSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF6Lk[1NFIh|ryP NEjCZoFUSU6JRWK=
MN-60 M{\KTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF7LkC1PVIh|ryP MmTOV2FPT0WU
EPLC-272H NWKxVYh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO3TWM2OD1zOT6zO|A5KM7:TR?= MWPTRW5ITVJ?
SW948 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXm4WlRWUUN3ME2xPU4{QTN2IN88US=> NWPxNHF2W0GQR1XS
MOLT-13 M{C2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPQTWM2OD1zOT60OVQ3KM7:TR?= MoO5V2FPT0WU
HL-60 MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJyLkKxOFEh|ryP NWrrSWlFW0GQR1XS
CP50-MEL-B NYTz[Jc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;iTWM2OD1{MD60O|Q5KM7:TR?= M2L4OHNCVkeHUh?=
NTERA-S-cl-D1 NG[1fHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\vTWM2OD1{MD60PVc5KM7:TR?= MVjTRW5ITVJ?
KINGS-1 MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLkTWM2OD1{MD63PVY4KM7:TR?= M{HRTHNCVkeHUh?=
DOHH-2 NYTZcIZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK1TWM2OD1{MD65NFYh|ryP Mnu4V2FPT0WU
BB65-RCC NXXY[WVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYewZ3JbUUN3ME2yNE46Ojh3IN88US=> MYjTRW5ITVJ?
NB12 MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnHZYNKSzVyPUKxMlA{QTRizszN NVWxTG5PW0GQR1XS
KY821 NFXMXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[5TWM2OD1{MT61PFIh|ryP NW\sUYdOW0GQR1XS
PSN1 NIXncWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHm[|FzUUN3ME2yNU43PDV|IN88US=> M2TVZnNCVkeHUh?=
EGI-1 M13rVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPK[ppKSzVyPUKxMlc1PTRizszN NEjXemtUSU6JRWK=
CTV-1 NGriPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXZZ5dCUUN3ME2yNk4{ODNzIN88US=> NVL4TJJbW0GQR1XS
TI-73 NXnnbGlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJ{LkO0PVgh|ryP M1ztU3NCVkeHUh?=
LCLC-103H M2HZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\LcGZKSzVyPUKyMlQ4PTJizszN NFjMWmlUSU6JRWK=
D-542MG NVv6WmpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkW2TWM2OD1{Mj61OVU5KM7:TR?= M1XqbnNCVkeHUh?=
ATN-1 NF\WPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTkSnBKSzVyPUKyMlY1OzlizszN MmD5V2FPT0WU
SK-MEL-1 NULhR25YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnrZZNRUUN3ME2yNk45OzZ6IN88US=> M1z6bXNCVkeHUh?=
HDLM-2 M4rKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGru[HJKSzVyPUKzMlE1PzhizszN NIPmS3JUSU6JRWK=
UM-UC-3 NYrSXIE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXSTWM2OD1{Mz6xPVQ1KM7:TR?= MnvVV2FPT0WU
NCI-H1573 NX;rPXNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjmXHpKSzVyPUKzMlQ3QDFizszN NGTVUGVUSU6JRWK=
NCI-H520 NGLxeXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK5[2NKSzVyPUKzMlQ6PDhizszN MXjTRW5ITVJ?
ESS-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYSz[5V4UUN3ME2yN{45ODV7IN88US=> MmjpV2FPT0WU
COR-L88 NI\6OopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJ|Lkm0O|Uh|ryP M4LkS3NCVkeHUh?=
TGBC24TKB MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L3dGlEPTB;MkSuNFMyOiEQvF2= MXrTRW5ITVJ?
HCC1937 NIXXd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXkTWM2OD1{ND6xJO69VQ>? MVjTRW5ITVJ?
RS4-11 MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDtTWM2OD1{ND6xOFIh|ryP MWHTRW5ITVJ?
HCC38 NWPNUpFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HMemlEPTB;MkSuNlM6PCEQvF2= Ml\aV2FPT0WU
RPMI-2650 MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJ2Lk[xOlIh|ryP NWLCRVhNW0GQR1XS
P12-ICHIKAWA MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3m1RmlEPTB;MkSuOlI2QCEQvF2= NVfkVGp7W0GQR1XS
YAPC NHT3Uo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3nTWM2OD1{ND64NlE1KM7:TR?= M1PU[HNCVkeHUh?=
NB13 NWPNO|Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWftfWJmUUN3ME2yOU4zPjFzIN88US=> MULTRW5ITVJ?
SK-N-AS M1HRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofUTWM2OD1{NT64OVg1KM7:TR?= M3LlVXNCVkeHUh?=
SK-N-DZ MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XEdGlEPTB;Mk[uNFQ6KM7:TR?= NXHHTXZLW0GQR1XS
LS-411N MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrHTnhCUUN3ME2yOk4zODN6IN88US=> M{TPT3NCVkeHUh?=
NCI-H810 NE\3SINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJ4LkOxNVIh|ryP NF:5U5hUSU6JRWK=
NCI-SNU-1 NIfJOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zBfmlEPTB;Mk[uOVQ2PCEQvF2= M2TqbHNCVkeHUh?=
HH NIPl[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXnXG5LUUN3ME2yOk42PTJ7IN88US=> Mn3XV2FPT0WU
U-2-OS NFyyTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJ4LkezPFIh|ryP NETDO3BUSU6JRWK=
SF539 M2S3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnDUJJKSzVyPUK2MlgxOThizszN M3G3WHNCVkeHUh?=
NCI-H2052 NH;FOlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzmTWM2OD1{Nz6wPFYh|ryP MmHCV2FPT0WU
A673 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJ5LkKxNFIh|ryP NEPZXmJUSU6JRWK=
WM-115 Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nyUmlEPTB;MkeuO|c3PyEQvF2= M3LDVHNCVkeHUh?=
SW48 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;DTWM2OD1{Nz64NFA2KM7:TR?= MXTTRW5ITVJ?
NOMO-1 MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJ5Lki1N|Ih|ryP NEniNpFUSU6JRWK=
PC-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly0TWM2OD1{Nz64PVQyKM7:TR?= Mkj1V2FPT0WU
UMC-11 NV6yU2hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkSwTWM2OD1{Nz65N|Q{KM7:TR?= NWfOcGdRW0GQR1XS
U-118-MG M2DuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn4TWM2OD1{OD6wNVI{KM7:TR?= MVzTRW5ITVJ?
NCI-H2452 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PWPGlEPTB;MkiuNFgzOiEQvF2= MXjTRW5ITVJ?
CAMA-1 M{HHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHHRZZzUUN3ME2yPE45PTZ2IN88US=> NITPVGRUSU6JRWK=
MC-IXC M13Ddmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJ7LkKzOlYh|ryP M1i1bnNCVkeHUh?=
ES4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHIUW9KSzVyPUK5MlMyPzJizszN NHXh[GhUSU6JRWK=
BHT-101 Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSzcHUyUUN3ME2yPU4{OjFizszN MorsV2FPT0WU
KP-4 MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHXT5lnUUN3ME2yPU42OTZizszN M2\QXnNCVkeHUh?=
CAL-54 M2rkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly5TWM2OD1{OT61OFQ2KM7:TR?= M3u2XnNCVkeHUh?=
5637 NVzIRXQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDXd3lKSzVyPUK5MlY1OjFizszN Ml:xV2FPT0WU
MOLT-16 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJ7LkeyOlkh|ryP M4PtN3NCVkeHUh?=
Ca-Ski M2PO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJ7Lkm0OkDPxE1? M{noPHNCVkeHUh?=
AsPC-1 NV7hXmlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTNyLkCyNVIh|ryP MoXsV2FPT0WU
MSTO-211H NFHqdWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPpRWppUUN3ME2zNE4yPSEQvF2= M4LQdXNCVkeHUh?=
L-428 NYjjTZlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17BPGlEPTB;M{CuOFA2KM7:TR?= M3v6UnNCVkeHUh?=
SW1463 NVHYNIt3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTNyLkWzPFMh|ryP NWTmZ3ZrW0GQR1XS
NCI-H1648 M3KwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP5eJBKSzVyPUOwMlU2PzRizszN NXzVeVNSW0GQR1XS
CAKI-1 NXH6dpFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojTTWM2OD1|MD63O|AzKM7:TR?= M3W1N3NCVkeHUh?=
YKG-1 NFu4VWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLGUmlCUUN3ME2zNU4xOjZ|IN88US=> M4i4V3NCVkeHUh?=
A2058 M4HRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTNzLkGxOlQh|ryP NVTTVGUxW0GQR1XS
A375 M3i0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TwdWlEPTB;M{GuNVY6PiEQvF2= MnuyV2FPT0WU
SNB75 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTNzLkK0N|Uh|ryP NVX2O3p4W0GQR1XS
SK-HEP-1 MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD0TWM2OD1|MT60NlcyKM7:TR?= M{fDdnNCVkeHUh?=
ME-180 M1fkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDXTWM2OD1|MT62OVQzKM7:TR?= MXTTRW5ITVJ?
NCI-H209 NYPYO2JjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTNzLkiyOFch|ryP MkjQV2FPT0WU
HC-1 MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nPWWlEPTB;M{KuNVQ1PiEQvF2= NXP2T2ZpW0GQR1XS
LB373-MEL-D M3fU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonnTWM2OD1|Mj6xPVcyKM7:TR?= MmOxV2FPT0WU
SNU-387 NY\yNo52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTN{LkOxPVEh|ryP MoHkV2FPT0WU
C32 MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULZSpFLUUN3ME2zNk4{OzV|IN88US=> NV30RW5EW0GQR1XS
EW-13 NEnzWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTN{Lkm0NFgh|ryP MofiV2FPT0WU
BFTC-905 NYm1U5FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\mNGlEPTB;M{OuOVE{PiEQvF2= NGXFe2hUSU6JRWK=
NCI-H1299 NXf5eGxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTN|LkW2NlEh|ryP NGf4W2ZUSU6JRWK=
LU-135 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnJbWFKSzVyPUOzMlgxOSEQvF2= NV7Oem9ZW0GQR1XS
NCI-H2122 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTN|Lkm5OlYh|ryP M1H4cnNCVkeHUh?=
SK-LMS-1 M1;uNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTLTVBuUUN3ME2zOE41OTB5IN88US=> NYjRN5h1W0GQR1XS
LNCaP-Clone-FGC MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmKwTWM2OD1|ND64OVE2KM7:TR?= MoTWV2FPT0WU
NCI-H1092 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjLUpZ1UUN3ME2zOU4zPzR5IN88US=> NX;wfIFHW0GQR1XS
MS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEiwN3JKSzVyPUO1MlMxOzhizszN NHjxOItUSU6JRWK=
KYSE-510 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm5WFRKSzVyPUO1MlUxPDJizszN MlfpV2FPT0WU
NCI-H1793 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HmOGlEPTB;M{WuOlU1PSEQvF2= M{Hj[HNCVkeHUh?=
MIA-PaCa-2 NIPZWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfhdHNKSzVyPUO2MlA1QTZizszN NHyzbFRUSU6JRWK=
EW-22 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPXcIVkUUN3ME2zOk41ODd{IN88US=> MofuV2FPT0WU
IGR-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTN4LkixPFQh|ryP NXvMfo9NW0GQR1XS
HT-1080 M{CzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\4fGFzUUN3ME2zO{4yOjVizszN MkLOV2FPT0WU
M14 MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Kzd2lEPTB;M{euNVY1OiEQvF2= NEXjd4VUSU6JRWK=
786-0 NV7ZVFFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXlS5pwUUN3ME2zO{4zPzl2IN88US=> NHjIRW9USU6JRWK=
MZ2-MEL M{SxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTN5LkS1NFEh|ryP NYLZRldUW0GQR1XS
NCI-H510A MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH5doJKSzVyPUO3Mlk1OTJizszN NWnZOI9RW0GQR1XS
LAN-6 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\nNZVtUUN3ME2zO{46PTh{IN88US=> MkLhV2FPT0WU
SW620 NHLWNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfCSIFKSzVyPUO4MlQ6PzRizszN MV;TRW5ITVJ?
LB2241-RCC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzJcXdVUUN3ME2zPU45OjB3IN88US=> M1rJR3NCVkeHUh?=
Detroit562 Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\oRZNFUUN3ME20NE4yOjZ6IN88US=> NV2wR5dNW0GQR1XS
HN NGq1dVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vPc2lEPTB;NECuNVc5OiEQvF2= NWTBXWN[W0GQR1XS
HCT-15 MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF74N4lKSzVyPUSwMlU6ODdizszN Mm\DV2FPT0WU
C2BBe1 NHG3Zo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDFTWM2OD12MD65NVU4KM7:TR?= NH\QdnhUSU6JRWK=
A498 Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DxUGlEPTB;NEGuN|AyPSEQvF2= NUPidW9[W0GQR1XS
SK-MEL-24 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnSXXlDUUN3ME20NU41PzJ3IN88US=> M3;pZ3NCVkeHUh?=
OVCAR-5 NW\FV2t7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fHT2lEPTB;NEGuO|c3PyEQvF2= NGrUfVZUSU6JRWK=
NCI-H1792 NFywT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTRzLkm4NlEh|ryP MoPvV2FPT0WU
KOSC-2 M{\YRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rBTGlEPTB;NEKuNlY6QSEQvF2= NHnmeo1USU6JRWK=
Mo-T NEG3Z4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTR{Lki5OVgh|ryP MV;TRW5ITVJ?
CFPAC-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nOT2lEPTB;NEOuOFk1PCEQvF2= MX\TRW5ITVJ?
CAL-51 NEHC[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2joU2lEPTB;NEOuOVYxPSEQvF2= NXnsT|ZZW0GQR1XS
RH-18 M4nSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\mfGlEPTB;NEOuPFA2KM7:TR?= M1PCSXNCVkeHUh?=
EC-GI-10 NEXYZ2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7kVINHUUN3ME20N{45OzR5IN88US=> NVPLZYhSW0GQR1XS
HSC-2 NVT5d5lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\JTWM2OD12ND6wNFkh|ryP MY\TRW5ITVJ?
ML-2 NGDscpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHxTWM2OD12NT6yOlIyKM7:TR?= MVHTRW5ITVJ?
KNS-81-FD NYXKPYZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e5PGlEPTB;NEWuO|M3PSEQvF2= MW\TRW5ITVJ?
NB6 NUfidIN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTMR|lNUUN3ME20Ok4yOTFizszN MmC1V2FPT0WU
MCF7 MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLWVIFKSzVyPUS2MlU2OzNizszN NGr2SnRUSU6JRWK=
P30-OHK NEHqeJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHYTWM2OD12Nj64NVE4KM7:TR?= MWrTRW5ITVJ?
BPH-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni5TWM2OD12Nj65PFA2KM7:TR?= M1\3SHNCVkeHUh?=
U251 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PifGlEPTB;NE[uPVk1KM7:TR?= NH25SnNUSU6JRWK=
MKN1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojGTWM2OD12Nz61NVM4KM7:TR?= M4P0fXNCVkeHUh?=
A431 M4jKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTR5LkizN|gh|ryP MWDTRW5ITVJ?
C8166 M3XtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTR7LkKwN|kh|ryP M2niNnNCVkeHUh?=
HEL MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTR7LkSwOlQh|ryP NE[xXZRUSU6JRWK=
RMG-I MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTR7LkS0OFQh|ryP MkfwV2FPT0WU
CAL-72 MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf1S4V{UUN3ME20PU43ODd3IN88US=> NXewc2RGW0GQR1XS
SW962 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmW2TWM2OD12OT65N|MzKM7:TR?= M3foSHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-c-kit / c-kit / p-AKT / AKT / p-ERK / ERK / p-STAT3 / STAT3 / p-STAT5 / STAT5 / p-S6K / S6K / p-S6 / S6; 

PubMed: 31205508     


Immunoblotting analysis of indicated proteins in c-KIT mediated signaling pathways of GIST-T1, GIST-882, GIST-48B, and GIST-5R cell lines.

PARP / cleaved PARP / caspase-3 / cleaved caspase-3; 

PubMed: 31205508     


Immunoblotting analysis of apoptosis-related proteins after axitinib treatment in human GIST cell lines. Imatinib and sunitinib were used as positive controls.

31205508
Immunofluorescence
alpha-tubulin; 

PubMed: 26474283     


Representative images of RCC cells treated as above described, and then immunostained with anti-α-tubulin antibody. Bar: 50 μM

26474283
Growth inhibition assay
Cell viability ; 

PubMed: 26474283     


A. A-498 and Caki-2 RCC cell lines were cultured up to 96 h with different doses of axitinib. Cell viability was determined by MTT assay. Data shown are expressed as mean ± SD of three separate experiments; *p < 0.01 vs vehicle-treated cells. B. RCC cell 䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€

26474283
In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

- Collapse

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

- Collapse
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% CMC
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736
Smiles CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=N[NH]3)\C=C\C4=CC=CC=N4

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04033991 Not yet recruiting Drug: Sunitinib|Drug: Axitinib Carcinoma|Renal Cell Pfizer September 2019 --
NCT03472560 Active not recruiting Drug: Avelumab (MSB0010718C)|Drug: Axitinib (AG-013736) Non-Small Cell Lung Cancer|Urothelial Cancer Pfizer May 2 2018 Phase 2
NCT03592199 Active not recruiting Drug: Sunitinib Clear Cell Renal Cell Carcinoma Instituto do Cancer do Estado de São Paulo|Pfizer December 11 2017 Phase 2
NCT03289533 Active not recruiting Drug: Avelumab (MSB0010718C)|Drug: Axitinib (AG-013736) Carcinoma Hepatocellular Pfizer September 8 2017 Phase 1
NCT00460603 Completed Drug: bevacizumab|Drug: AG-013726|Drug: AG-013736 (axitinib) Colorectal Neoplasms Pfizer January 2006 Phase 1|Phase 2
NCT00219557 Completed Drug: Gemcitabine|Drug: AG-013736 Pancreatic Neoplasms Pfizer July 5 2005 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID